CN111973551A - Mussel mucin antibacterial gel and preparation method thereof - Google Patents
Mussel mucin antibacterial gel and preparation method thereof Download PDFInfo
- Publication number
- CN111973551A CN111973551A CN202010891870.8A CN202010891870A CN111973551A CN 111973551 A CN111973551 A CN 111973551A CN 202010891870 A CN202010891870 A CN 202010891870A CN 111973551 A CN111973551 A CN 111973551A
- Authority
- CN
- China
- Prior art keywords
- mussel mucin
- chitosan
- raw materials
- sodium hyaluronate
- mussel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000237536 Mytilus edulis Species 0.000 title claims abstract description 61
- 235000020638 mussel Nutrition 0.000 title claims abstract description 61
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 238000001879 gelation Methods 0.000 title description 2
- 102000015728 Mucins Human genes 0.000 claims abstract description 55
- 108010063954 Mucins Proteins 0.000 claims abstract description 55
- 239000002994 raw material Substances 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920001661 Chitosan Polymers 0.000 claims abstract description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 11
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 11
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 11
- 239000008213 purified water Substances 0.000 claims abstract description 9
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 7
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004327 boric acid Substances 0.000 claims abstract description 7
- 229960001631 carbomer Drugs 0.000 claims abstract description 7
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 7
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims abstract description 7
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims abstract description 7
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940041616 menthol Drugs 0.000 claims abstract description 7
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 102000007298 Mucin-1 Human genes 0.000 claims abstract description 5
- 108010008707 Mucin-1 Proteins 0.000 claims abstract description 5
- 230000003385 bacteriostatic effect Effects 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000011265 semifinished product Substances 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000029663 wound healing Effects 0.000 abstract description 7
- 208000006374 Uterine Cervicitis Diseases 0.000 abstract description 6
- 206010008323 cervicitis Diseases 0.000 abstract description 6
- 208000003251 Pruritus Diseases 0.000 abstract description 5
- 230000003628 erosive effect Effects 0.000 abstract description 5
- 230000003020 moisturizing effect Effects 0.000 abstract description 5
- 210000004400 mucous membrane Anatomy 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 230000007803 itching Effects 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 42
- 238000012360 testing method Methods 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 210000004877 mucosa Anatomy 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 7
- 206010051814 Eschar Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 231100000333 eschar Toxicity 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 230000001568 sexual effect Effects 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000019300 CLIPPERS Diseases 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
The invention discloses a mussel mucin antibacterial gel and a preparation method thereof, wherein the mussel mucin antibacterial gel comprises the following raw materials in percentage by mass: mussel mucin 1%, boric acid 0.2%, sodium hyaluronate 0.1% with 30 ten thousand molecular weight, chitosan 0.3-1.0%, menthol 0.1-0.5%, chlorhexidine acetate 0.2-0.5%, carbomer 9400.8-1.5%, ethanol 0.5-1.0%, ethylparaben 0.01-0.05%, triethanolamine 0.05-0.1%, and purified water 90-98%, wherein the total mass percentage of the components is 100%. The mussel mucin antibacterial gel is prepared by compounding mussel mucin, sodium hyaluronate, chitosan and the like, and has the effects of quickly repairing and moisturizing private mucous membranes, resisting oxidation, inhibiting bacteria and relieving itching, promoting wound healing, balancing flora and assisting in treating cervicitis, cervical erosion and various inflammations through the synergistic effect of the mussel mucin, the sodium hyaluronate and the chitosan.
Description
Technical Field
The invention belongs to the fields of medicine and personal care, and particularly relates to an antibacterial gel and a preparation method thereof.
Background
Data show that 86% of women worldwide do not know the severity of female personal care problems and neglect the importance of the personal care problems, and data show that the personal care problems can become invisible killers affecting female health in the future. Unfortunately, the personal care problem of 60% of women worldwide is further aggravated and becomes a disease, and many women will face double troubles from marital and health if the personal care problem cannot be solved and looked at in time.
Women like flowers, eager to have beautiful appearance and high-priced temperament are the beauty-pleasing nature of women. So that so many women have their efforts and time spent making up and shopping. The clothes can be more beautiful, make-up can be younger, but the most mysterious parts need to be maintained, and maintenance in private parts can make the whole person younger and healthier. If neglected, the personal health problem is not only hurt but also the family happiness is affected along with the time lapse, the age increase and the occurrence of the private health problem.
Disclosure of Invention
The invention aims to provide a mussel mucin antibacterial gel and a preparation method thereof, the mussel mucin antibacterial gel is prepared by compounding mussel mucin, sodium hyaluronate, chitosan and the like, and has the effects of quickly repairing and moisturizing private mucous membranes, resisting oxidation, inhibiting bacteria, relieving itching, promoting wound healing, balancing flora and assisting in treating cervicitis, cervical erosion and various inflammations through the synergistic effect of the mussel mucin, the sodium hyaluronate and the chitosan.
The technical scheme of the invention is as follows:
the mussel mucin antibacterial gel is characterized by being prepared from the following raw materials in percentage by mass: mussel mucin 1%, boric acid 0.2%, sodium hyaluronate 0.1% with 30 ten thousand molecular weight, chitosan 0.3-1.0%, menthol 0.1-0.5%, chlorhexidine acetate 0.2-0.5%, carbomer 9400.8-1.5%, ethanol 0.5-1.0%, ethylparaben 0.01-0.05%, triethanolamine 0.05-0.1%, and purified water 90-98%, wherein the total mass percentage of the components is 100%.
The mussel mucin antibacterial gel is characterized by being prepared from the following raw materials in percentage by mass: mussel mucin 1%, boric acid 0.2%, 30 ten thousand molecular weight sodium hyaluronate 0.1%, chitosan 0.4%, menthol 0.4%, chlorhexidine acetate 0.25%, carbomer 9401.0%, ethanol 0.8%, ethylparaben 0.03%, triethanolamine 0.08%, and purified water 95.74%, wherein the total mass percentage of the components is 100%.
A preparation method of mussel mucin antibacterial gel is characterized by comprising the following steps:
(1) cleaning and selecting required raw materials, and respectively weighing the raw materials according to the mass percentage for later use;
(2) dissolving the mussel mucin, the sodium hyaluronate and the chitosan weighed in the step (1) by 10 times of purified water respectively, and mixing to obtain transparent solution for later use;
(3) soaking carbomer and boric acid weighed in the step (1) in a proper amount of purified water for 24 hours, and uniformly stirring to obtain a soaking solution for later use;
(4) dissolving chlorhexidine acetate, ethylparaben and menthol with the ethanol weighed in the step (1) to obtain a dissolved solution for later use;
(5) adding the dissolved solution obtained in the step (4) into the soaking solution obtained in the step (3), uniformly stirring, adding the transparent solution obtained in the step (2) into the soaking solution obtained in the step (3), mixing and stirring, adding triethanolamine and stirring, and stirring for 4-5 hours in total to obtain a semi-finished bacteriostatic gel;
(6) passing through a colloid mill, inspecting the semi-finished product to be qualified, vacuumizing and filtering by using a vacuum pump, rotating at a rotating speed of-0.95 mpa for 10 minutes, and averaging for 10 minutes;
(7) filling 3 g/per bottle, wherein the net content allows negative deviation to be 9.0%;
(8) and packaging, inspecting finished products and warehousing.
The invention has the following positive effects:
(1) the mussel mucin antibacterial gel provided by the invention is simple in preparation method, convenient to use and suitable for large-scale popularization and use.
(2) In the field of female personal care, the mussel mucin antibacterial gel is a head-money-in-China cervical gel for word-eliminating repair made of mussel mucin by adopting the material characteristics.
(3) The mussel mucin antibacterial gel provided by the invention is scientific in formula, and the used raw materials and auxiliary materials are safe and non-irritating, and have the effects of quickly repairing and moisturizing private mucous membranes, resisting oxidation, inhibiting bacteria, relieving itching, promoting wound healing, balancing flora and assisting in treating cervicitis, cervical erosion and various inflammations.
Drawings
Fig. 1 is a flow chart of a preparation process of the mussel mucin bacteriostatic gel.
Fig. 2 is a comparison chart of the experiment for repairing mucosal injury, wherein a is a mucosal image of mussel mucin, and b is a mucosal image after mussel mucin treatment.
Table 1 is a data table of raw materials in the mussel mucin bacteriostatic gel of the invention
Performance test of mussel mucin bacteriostatic gel
1. And (3) testing the irritation of the mussel mucin antibacterial gel to the vaginal mucosa.
2. And (3) testing a sample: the mussel mucin antibacterial gel is gel, and an original sample is taken as a tested object.
3. Experimental animals: female New Zealand white rabbits 6 were provided by Dialep, Seisan, Bio-medicine, Inc., weighing 2.1-2.4 kg.
Common level, production license number: SCXK (shan) > 2019002. The feed source is the same as above.
4. Animal room environment: ordinary ambient temperature: 18 ℃ -29 ℃, relative humidity: 40-70 percent of the total weight of the animal experiment, and the license number used by the experimental animal is SYXK (shan) 2019-.
5. The test method comprises the following steps: the 6 non-estrus domestic rabbits were randomly divided into 2 groups, i.e., a contaminated group and a control group, each group consisting of 3 rabbits, and during the test, the animals were fixed on their backs, the perineum and vaginal opening were exposed, the catheter was gently inserted into the vagina of 4cm-5cm, 2g of the test substance was slowly injected with a syringe, and the animals in the control group were treated with physiological saline in the same manner. Killing animals 24h after the last infection, taking out the complete vagina by adopting an air embolism method, carrying out laparotomy, carrying out visual observation on whether congestion, edema and other manifestations exist, then putting the vagina into 10% formalin solution for fixation for more than 24h, selecting tissues at two ends and the center of the vagina for flaking, carrying out histopathological examination after HE staining, and carrying out evaluation according to the vagina mucosa irritation reaction scoring standard.
6. The test results are shown in Table 2
TABLE 2 results of the experiment on the irritation of mussel mucin gel to rabbit's vaginal mucosa
7. Evaluation of
According to the vaginal mucosa stimulation intensity powder standard in the technical Specification for disinfection products, the vaginal mucosa stimulation index of the mussel mucin bacteriostatic gel is 0.22, and the stimulation reaction intensity is nonirritant.
Table 3 is a statistical table of the results of the female cervicitis gynecological disease irritation test
As can be seen from the table 3, no matter the mussel mucin antibacterial gel is applied to the vaginal mucosa without cervicitis and gynecological diseases or the vaginal mucosa with cervicitis and gynecological diseases, no stinging sensation is caused to a person in the using process, and the skin is free from swelling and irritation after 24 hours. The mussel mucin antibacterial gel provided by the invention is basically non-irritant to vaginal mucosa.
Secondly, bacteriostasis test of the mussel mucin bacteriostasis gel
1. Test equipment
1.1 test strains: escherichia coli (8099). Cultured for 7 generations. Staphylococcus aureus (ATCC6538) was cultured for 7 generations, Candida albicans (ATCC10231) was cultured for 7 generations. Provided by China center for preservation and management of industrial microbial species.
1.2 sample: mussel mucin bacteriostatic gel.
1.3 vector: the filter paper sheet was 10cm by 1.0 cm.
1.4 nutrient agar, Sha's agar was provided by Beijing Luqiao technology GmbH.
1.50.03 mol/L Phosphate Buffer Solution (PBS).
1.6 sterile graduated pipette, plate, test tube, thermostatic wall culture box (type 303-3), etc.
2. Inspection method
2.1 according to GB15979-2002 hygienic Standard for Disposable sanitary articles).
2.2 the bacteriostatic test is a carrier test, the test temperature is 20 +/-1 ℃, and the test is repeated three times.
3. Test results
The mussel mucin antibacterial gel has the effect of 5mim, the average antibacterial rate on escherichia coli (8099) reaches 100%, the average antibacterial rate on staphylococcus aureus (ATCC6538) reaches 100%, and the average antibacterial rate on candida albicans (ATCC10231) reaches 100%. The results are shown in tables 4, 5 and 6.
TABLE 4 bacteriostatic effect of mussel mucin gel on E.coli
Note: the average number of producing colonies in the positive control group was 2.66X 104cfu/disc, negative control sterile growth.
TABLE 5 bacteriostatic Effect of mussel mucin gel on Staphylococcus aureus
Note: the average number of producing colonies in the positive control group was 2.27X 104cfu/disc, negative control sterile growth.
TABLE 6 bacteriostatic Effect of mussel mucin gel on Candida albicans
Note: the average number of producing colonies in the positive control group was 2.37X 104cfu/disc, negative control sterile growth.
Toxicity test of mussel mucin bacteriostatic gel
1. Preparation before testing
60 mice are treated by electric hair clippers before administration, the hair removal area of the mice along the two sides of the spine is 2 multiplied by 2cm, the hair removal area of the mice is observed to be damaged due to hair removal after 24 hours, and the mice cannot be used as a complete skin group experiment if the skin is damaged; the 60 mice were divided into 6 groups of 10 mice each, each group having half male and female, groups 1-3 being intact skin groups, groups 4-6 being damaged skin groups. Among them, 30 mice in the group with damaged skin were subjected to skin scratch with fine sandpaper in the depilated area, with no damage to the dermis and slight bleeding as the standard. Group 1 was an intact skin blank control group; group 2 is a group of intact skin low dose medications; group 3 is a group of intact skin high dose medications. Group 4 is a damaged skin blank control group; group 5 is a group of low dose drugs for damaged skin; group 6 is a group of high dose drugs for damaged skin.
2. Test procedure
Coating 0.5g of the mussel mucin antibacterial gel consisting of the raw materials described in example 1 on a low-dose medicine application group in a depilation area, coating 1g of the mussel mucin antibacterial gel consisting of the raw materials described in example 1 on a high-dose medicine application group in the depilation area, cleaning an administration part by using a sodium chloride solution with the concentration of 0.9% after 24 hours of coating, then continuing to feed according to a conventional feeding method, simultaneously recording the time of toxicity appearance and disappearance, removing 1h of the medicine as a first observation point, then respectively carrying out observation and recording for 8h, 24h and 48h, and if the toxicity appears after 48h, continuing to observe and record. Attention is paid to the red and swollen degree of the drug-coated area of the white mouse, the hair color, the body weight, the change of eyes and mucous membranes, the activity of limbs and other performance manifestations.
3. Test results
Through observation, the skin luster of the medicine-coated areas of the mice of the groups 2, 3, 5 and 6 is basically not different from that of the groups 1 and 4 of the control group, the mice can move freely, the eyes and the mucous membranes are not abnormal, the weight change is kept in a reasonable range, and no mice die, which shows that the mussel mucin bacteriostatic gel has no acute toxic reaction.
4. Wound healing test
4.1, preparation before testing
The method comprises the steps of removing hair areas of 16 mice with SPF (specific pathogen free) grades, the body weights of 150 +/-10 g and half of males and females along two sides of a spine by using an electric hair clipper before administration, then carrying out anesthesia on the mice, wherein the dosage of an anesthetic is the same standard, marking 1 circle with the diameter of 1cm at the hair removal position, disinfecting the circle with iodine, and then removing the whole skin of the marked two circles by using a medical clipper to form two circular wound surfaces.
4.2 test procedure
The mice are divided into 2 groups, each group comprises 8 mice, each mouse is half male and female, the 1 st group is the mussel mucin bacteriostatic gel prepared from the raw materials described in the example 1, and the 2 nd group is common external normal saline. The two groups of mice begin to take the medicine after 0.5 hour after the wound, the interval time is 4 hours, the medicine is continuously taken for 24 days, and the dosage is 1 mL; the mental state of the rats and the time to wound onset scab, as well as the time to wound onset scab, were recorded daily.
Table 7 shows the healing time of the wounds of different groups of mice
| Serial number | Scab formation time (h) | Decrustation time (h) |
| Group 1 | 75 | 340 |
| Group 2 | 165 | 503 |
4.3 test results
As can be seen from Table 7, the eschar time and the eschar time appeared to be positively correlated, and the eschar time was earlier in group 1 with the earlier eschar time, and the eschar skin at the wound was smoother. Compared with normal saline, the mussel mucin antibacterial gel prepared from the raw materials in the embodiment 1 of the invention can effectively shorten the scabbing time and the decrustation time, and the mussel mucin antibacterial gel prepared from the raw materials in the embodiment 1 of the invention has better effects of diminishing inflammation and promoting wound healing.
5. Moisture retention test
The instrument is a silica gel dryer, the ambient temperature is 25 ℃, and the experimental object is the mussel mucin bacteriostatic gel consisting of the raw materials in the embodiment 1.
The test process comprises the following steps: weigh the vial by a weight denoted CAir conditioner2g of the mussel mucin bacteriostatic gel prepared from the raw materials described in example 1 was placed in a weighing bottle, and the mass of the gel was accurately weighed and recorded as C0Placing in a silica gel dryer, standing for 1, 3, 5, 7, 9, 11, 13, 15, 17, 21, and 24 hours (h), weighing again, and recording as Cn；
The water loss rate is calculated as follows:
water loss (%) - (C)0-Cn)/(C0-CAir conditioner) X 100%, in the formula,Cair conditionerEmpty weighing bottle mass, C0The mass of a weighing bottle for holding 2g of the mussel mucin bacteriostatic gel consisting of the raw materials described in example 1, CnThe mass of the weighing bottle for containing the mussel mucin antibacterial gel after being placed for n hours.
Moisture retention (%) - (100% water loss (%)
The lower the water loss rate, the better the moisturizing effect.
Table 8 is a moisture retention test data table
As can be seen from table 8, the moisture retention of the mussel mucin antibacterial gel of the invention can still reach 98.80% after 24 hours, and the moisture retention rate of the commonly used humectant glycerin in skin care products is as follows: moisture retention of 96% and L-lysine hydrochloride: 87.6% (data from the literature, "moisture absorption and retention and kinetics of laminine"). The mussel mucin bacteriostatic gel has a good moisturizing effect.
6. Control of mucosal injury repair experiment
Mussel mucin contains a large amount of lysine and carries a high amount of positive charge at physiological ph values. The human tissues are negatively charged, the proteins are quickly adsorbed to the surfaces of the cells by positive and negative attraction to form a non-continuous micro-nano biological scaffold, and the support and the direction are provided for the adherence and crawling of the cells through the electrostatic physical action, so that the tissue reconstruction is facilitated, the wound healing is promoted, and the bacteriostatic action is realized. Has good effect on mild and moderate cervical erosion.
7. Anti-inflammatory
The characteristic has obvious effect on aseptic vaginitis and senile vaginitis.
8. Oxidation resistance
With age, oxygen radicals gradually destroy body cellular tissues, leading to aging. Mussel mucin contains 10% of dopa group, and is the only known protein with high content of dopa group, so that it can resist aging, prevent the generation of new melanin, make mucosa tender, and quickly relieve pruritus.
Fourth, applicable therapeutic scenario
1. Postoperative maintenance
And (3) postoperative care: within 7 days after treatment, one part of the Chinese medicinal composition is used every day to promote wound healing and repair and maintain the health of the wound.
2. Domestic maintenance
Indications are as follows: wrinkle disappearance, mucosa thinning, and other symptoms of intimate aging, including dryness, pruritus, odor, and laxity. Promoting the youthfulness of privacy, inhibiting melanin, and increasing sensitivity, thereby improving the pleasure of sexual life. (recommended daily maintenance 2-3 per week)
3. Sexual life
The use before sexual life can form a barrier to prevent virus infection and has lubricating effect to relieve pain of sexual life; can repair mucosa injury after sexual life, recover vaginal environment, and has effects of relieving and caring.
4. Gynecological application
Indications are as follows: repairing mucosa wound, aseptic/senile vaginitis, cervical erosion, and repairing and healing induced abortion and puerperal abortion.
5. Daily care
The people paying attention to daily maintenance can be used for daily private nursing.
The foregoing is a more detailed description of the invention in connection with specific preferred embodiments and is not intended to limit the invention to the particular forms disclosed. For those skilled in the art to which the invention pertains, several simple deductions or substitutions can be made without departing from the spirit of the invention, and all shall be considered as belonging to the protection scope of the invention.
Claims (4)
1. The mussel mucin antibacterial gel is characterized by being prepared from the following raw materials in percentage by mass: mussel mucin 1%, boric acid 0.2%, sodium hyaluronate 0.1% with 30 ten thousand molecular weight, chitosan 0.3-1.0%, menthol 0.1-0.5%, chlorhexidine acetate 0.2-0.5%, carbomer 9400.8-1.5%, ethanol 0.5-1.0%, ethylparaben 0.01-0.05%, triethanolamine 0.05-0.1%, and purified water 90-98%, wherein the total mass percentage of the components is 100%.
2. The mussel mucin bacteriostatic gel according to claim 1, which is prepared from the following raw materials in percentage by mass: mussel mucin 1%, boric acid 0.2%, 30 ten thousand molecular weight sodium hyaluronate 0.1%, chitosan 0.4%, menthol 0.4%, chlorhexidine acetate 0.25%, carbomer 9401.0%, ethanol 0.8%, ethylparaben 0.03%, triethanolamine 0.08%, and purified water 95.74%, wherein the total mass percentage of the components is 100%.
3. A method for preparing a mussel mucin bacteriostatic gel according to claim 1 or 2, which comprises the following steps:
(1) cleaning and selecting required raw materials, and respectively weighing the raw materials according to the mass percentage for later use;
(2) dissolving the mussel mucin, the sodium hyaluronate and the chitosan weighed in the step (1) by 10 times of purified water respectively, and mixing to obtain transparent solution for later use;
(3) soaking carbomer and boric acid weighed in the step (1) in a proper amount of purified water for 24 hours, and uniformly stirring to obtain a soaking solution for later use;
(4) dissolving chlorhexidine acetate, ethylparaben and menthol with the ethanol weighed in the step (1) to obtain a dissolved solution for later use;
(5) adding the dissolved solution obtained in the step (4) into the soaking solution obtained in the step (3), uniformly stirring, adding the transparent solution obtained in the step (2) into the soaking solution obtained in the step (3), mixing and stirring, adding triethanolamine and stirring, and stirring for 4-5 hours in total to obtain a semi-finished bacteriostatic gel;
(6) passing through a colloid mill, inspecting the semi-finished product to be qualified, and performing vacuum pumping and filtration by using a vacuum pump;
(7) filling 3 g/per bottle, wherein the net content allows negative deviation to be 9.0%;
(8) and packaging, inspecting finished products and warehousing.
4. The method for preparing a mussel mucin bacteriostatic gel according to claim 3, wherein the method comprises the following steps: and (6) the vacuum degree of the step (6) is 0.95mpa, the rotating speed is 45 revolutions for 10 minutes, and the average value is 10 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010891870.8A CN111973551A (en) | 2020-08-31 | 2020-08-31 | Mussel mucin antibacterial gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010891870.8A CN111973551A (en) | 2020-08-31 | 2020-08-31 | Mussel mucin antibacterial gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111973551A true CN111973551A (en) | 2020-11-24 |
Family
ID=73441044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010891870.8A Pending CN111973551A (en) | 2020-08-31 | 2020-08-31 | Mussel mucin antibacterial gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111973551A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114767924A (en) * | 2022-04-29 | 2022-07-22 | 海南德诺海思生物科技有限公司 | Preparation method of mussel-like mucin hydrogel suitable for repairing damaged skin cells |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104645320A (en) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | Mussel mucoprotein gel for wound repair, and preparation method and application thereof |
| CN104645313A (en) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | Mussel mucoprotein gel for repairing and reliving itching and preparation method of mussel mucoprotein gel |
| CN105392468A (en) * | 2013-05-20 | 2016-03-09 | 高敏 | Preparation method of mussel adhesive protein gel, mussel adhesive protein gel and use thereof |
| CN108853409A (en) * | 2018-08-13 | 2018-11-23 | 西安中天生物医药有限公司 | A kind of propolis aloetic bacteriostatic gel and preparation method thereof |
| CN110917120A (en) * | 2019-11-25 | 2020-03-27 | 四川艾医生医疗科技有限公司 | Sticky antibacterial repairing material and preparation method and application thereof |
-
2020
- 2020-08-31 CN CN202010891870.8A patent/CN111973551A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105392468A (en) * | 2013-05-20 | 2016-03-09 | 高敏 | Preparation method of mussel adhesive protein gel, mussel adhesive protein gel and use thereof |
| CN104645320A (en) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | Mussel mucoprotein gel for wound repair, and preparation method and application thereof |
| CN104645313A (en) * | 2015-01-28 | 2015-05-27 | 南京航空航天大学 | Mussel mucoprotein gel for repairing and reliving itching and preparation method of mussel mucoprotein gel |
| CN108853409A (en) * | 2018-08-13 | 2018-11-23 | 西安中天生物医药有限公司 | A kind of propolis aloetic bacteriostatic gel and preparation method thereof |
| CN110917120A (en) * | 2019-11-25 | 2020-03-27 | 四川艾医生医疗科技有限公司 | Sticky antibacterial repairing material and preparation method and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114767924A (en) * | 2022-04-29 | 2022-07-22 | 海南德诺海思生物科技有限公司 | Preparation method of mussel-like mucin hydrogel suitable for repairing damaged skin cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6761453B2 (en) | Antibacterial application of poly-N-acetylglucosamine nanofibers | |
| US20160367504A1 (en) | Petrolatum-based compositions comprising cationic biocides | |
| CN108452295A (en) | A kind of compact gel and preparation method antibacterial, that adjust microecological balance | |
| CN107802825A (en) | A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa | |
| CN108096396A (en) | A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa | |
| CN113081928A (en) | Plant bacteriostatic gel and preparation method and application thereof | |
| CN108420789B (en) | Benzalkonium chloride solution for external use and preparation method thereof | |
| CN101543658B (en) | Cervical cap for preventing and treating cervical erosion and preparation method thereof | |
| CN111228458A (en) | External biological preparation for preventing and treating colpitis and preparation method thereof | |
| CN109010124B (en) | Marine refined gynecological antibacterial gel and preparation method thereof | |
| CN111973551A (en) | Mussel mucin antibacterial gel and preparation method thereof | |
| CN109833431A (en) | A kind of bacteriostatic gel and preparation method thereof | |
| CN103249419A (en) | Compositions with antibacterial and wound healing activity | |
| CN107149569A (en) | A kind of antipruritic skin gels composition | |
| CN108096276A (en) | A kind of debridement healing washing lotion and its application | |
| CN111920911B (en) | Mosquito-proof disinfectant and preparation method thereof | |
| CN106943425A (en) | A kind of gynaecology sterilization gel of wound healing and preparation method and application | |
| CN106880698A (en) | A kind of plants essential oil and preparation method for treating child's property vaginitis | |
| CN109453146B (en) | Pathogenic microorganism resisting composition and preparation method and application thereof | |
| RU2535141C1 (en) | Gel composition of wide spectrum of biological action | |
| CN101757119B (en) | Medicine composition for treating vaginitis as well as gel and preparation method thereof | |
| CN110193004A (en) | Women bacteriostatic gel and preparation method thereof containing biological bacteriostatic peptide | |
| JPH0240326A (en) | Drug composition and its preparation | |
| CN114848582B (en) | Sustained-release antibacterial gel for treating female vulvar leukoplakia and preparation method thereof | |
| CN115300576B (en) | Compound traditional Chinese medicine nanogel for treating beriberi and tinea pedis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201124 |